Skip to main content
Fig. 4 | Acta Neuropathologica Communications

Fig. 4

From: Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination

Fig. 4

The titer, but not epitope, of human MOG Ab changes over time. a Compared to the sample at baseline, MOG Ab titers, represented by DEP, decreased by more than 30% (blue-filled) in 13/19 paediatric (68%) and 14/32 adult sera (44%), and increased by more than 30% (green-filled) in 4/19 children (21%) and 6/32 adults (19%) for up to 4.7 years (median 17.6 months, IQR 3.6–28.9) and 9.1 years (median 4.1 months, IQR 1.7–13.9), respectively. Dotted lines represent native-MOG Ab titer (100%) at the baseline sample of each patient. b Native-MOG Ab immunoreactivity toward P42 did not change regardless of initial native-P42 Ab titers in all 17 paediatric and 24/27 adult (89%) native-P42 Ab-seropositive patients for up to 4.7 and 9.1 years, respectively. Two adults with high titers of native-P42 Ab decreased (blue), and one adult developed high immunoreactivity to native-P42 (green). c and d Sera collected during active disease (n = 13 paediatric and n = 12 adult samples, red) and disease remission (n = 15 paediatric and n = 12 adult samples, blue) were available in 10 children and 10 adults. c Native-MOG Ab titers were higher during acute samples than remission samples (P = 0.006, children; P = 0.004, adults). d Among 9 children and 7 adults recognizing native-P42, 8/9 children and 6/7 adults had slightly weaker immunoreactivity to native-P42 during remission (children, P = 0.317; adults, P = 0.226). Ab = antibody, DEP = dilution end-point, native-MOG = native human MOG, native-P42 Ab = native Proline42 binding MOG Ab

Back to article page
\